Under DPCO, 2013, ceiling prices fixed and notified in generic name of medicines are applicable to all brands of the same medicines as specified in Schedule-I of the said order. No person is authorized to sell any scheduled formulation (medicine) to a consumer at a price exceeding the price notified by the NPPA. In respect of medicines not under price control, manufacturers are allowed to increase maximum retail price (MRP) by 10% annually.
The National Pharmaceutical Pricing Policy (NPPP) was notified on 7th December, 2012 with the objective to put in place a regulatory framework for pricing of drugs so as to ensure availability of required medicines ��essential medicines� at reasonable prices even while providing sufficient opportunity for innovation and competition to support the growth of pharma industry thereby meeting the goals of employment and shared economic well-being for all. It aims to bring the prices of essential medicines, as listed under National List of Essential Medicines-2011, under price control.
The Department of Pharmaceuticals has notified the National Pharmaceutical Pricing Policy -2012 under which the prices of National List of Essential Medicines-2011 are to be controlled & regulated on the basis of Simple Average Price of all the brands having market share (on the basis of Moving Annual Turnover) more than and equal to 1% of the total market turnover of that medicine.
This information was given by the Minister of State for Chemicals & Fertilizers Shri Hansraj Gangaram Ahir in reply to an Unstarred Question in the Lok Sabha today.